| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Dyadic International, Inc.
$0.88
-0.17 (-16.19%)
Market Cap
32.07 M
EPS
-0.21
P/E Ratio
-
Value Trade
124.72 K
SEC Financials
Q2 2026Dilution Risk
Revenue
961.14 K
R&D Expenses
332.62 K
Total Assets
6.54 M
Total Liabilities
8.92 M
Equity
-2.39 M
-13.73 %
Week
-27.27 %
1 Month
27.54 %
3 Month
6.67 %
6 Month
%
5 Year
%
All Time
Cash Data
Cash Position
3.11 M
Monthly Burn
685.00 K
Runway
4.5 mo
Burn Trend
StableSEC Filing
Aug 12, 2026
Overview
Volume
429.31 K
52 Week Range
0.65 - 1.60
% held by Insiders
25.31 %
% held by Institutions
13.84 %
Enterprise Value
28.95 M
Total Shares
36.45 M
Short %
0.2 %
Float Shares
26.98 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Dyadic International, Inc.
118Total events
2Upcoming
20Tier-1 (high impact)
2004 – 2026Coverage
Upcoming catalysts 2
TBD
T2Timing Guidance
Subscribe to view catalyst details
TBD
T1NDA Submission
Subscribe to view catalyst details
Event history 2
TBD
▲Platform ValidationPreclinical
Subscribe to view catalyst details
TBD
◆Timing GuidancePresentation
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
Drug Pipeline Intelligence
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in DYAI
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
DYAI Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-08-21 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-08-21 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-08-21 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
-DYAI
Aug 13, 2026▼ -16.2%today
Dyadic International, Inc. Secures $2.9 Million Through Registered Direct Offering and Concurrent Private Placement
Dyadic International, Inc. has announced a registered direct offering and concurrent private placement, securing approximately $2.9 million. The offering includes the sale of 3,625,000 shares of Common Stock at $0.795 each. The funds will be utilized for general corporate purposes and working capital, with the transaction expected to close by August 14, 2026.
Read more →-DYAI
Jul 7, 2026▲ +9.5%on this news
Global Collaborations Continue to Validate Dyadic’s C1 Platform and Expands Commercial Potential
Dyadic International highlights the progress of its C1 protein production platform through various global health collaborations. The platform has demonstrated its ability to produce monoclonal antibodies and vaccine antigens efficiently and cost-effectively. Recent funding from the Gates Foundation and partnerships with CEPI and Scripps Research further validate C1's potential in addressing urgent health challenges.
Read more →-DYAI
Jun 29, 2026▲ +9.9%on this news
Dyadic Expands IP Protection and Business Development Activities in Japan
Dyadic International has received patent approval from the Japan Patent Office for its Thermothelomyces heterothallica recombinant protein expression technology. This milestone strengthens Dyadic's intellectual property portfolio and supports its expansion strategy in Japan. The company is also collaborating with Intralink to enhance business development activities in key markets.
Read more →-DYAI
Jun 15, 2026▲ +16.7%on this news
Dyadic Highlights Accelerated Interest in C1 Biomanufacturing Platform Amid Ebola Preparedness Activities and Growing Commercial Adoption
Dyadic International is experiencing heightened interest in its C1 biomanufacturing platform amid the ongoing Bundibugyo Ebola virus outbreak. The platform's rapid production capabilities are seen as crucial for developing vaccines and monoclonal antibodies efficiently. Dyadic is pursuing multiple collaborations to enhance its platform's application in infectious disease preparedness and commercial markets.
Read more →-DYAI
Jun 15, 2026▲ +16.7%on this newsshared move
Dyadic Highlights Accelerated Interest in C1 Biomanufacturing Platform Amid Ebola Preparedness Activities and Growing Commercial Adoption Company's C1 platform may help address urgent need for rapid, scalable vaccine and
Dyadic International, Inc. highlighted the increasing interest in its C1 biomanufacturing platform, especially in response to the Bundibugyo Ebola virus outbreak. The platform aims to expedite the manufacturing of vaccines and monoclonal antibodies, which are crucial during health emergencies. Recent collaborations with organizations like Scripps Research aim to advance the development of vaccine antigens for various infectious diseases. Dyadic's C1 platform is also viewed as a versatile solution that can support multiple industries, including food and industrial markets, indicating its commercial potential.
Read more →-DYAI
May 28, 2026▼ -6.6%on this news
Dyadic and Scripps Research Collaborate on Rapid-Response Hantavirus Antibody and Vaccine Development
Dyadic International is collaborating with Scripps Research to develop monoclonal antibodies and vaccines targeting hantaviruses, particularly the Andes virus. This partnership aims to enhance pandemic preparedness by utilizing Dyadic's C1 platform for rapid and scalable biologic production. The collaboration builds on previous work and seeks to address challenges in manufacturing during public health emergencies.
Read more →-DYAI
May 21, 2026Dyadic to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026
Dyadic International, Inc. will participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026. The event includes a webcast presentation and opportunities for one-on-one meetings with investors. Dyadic focuses on producing precision-engineered, animal-free proteins and enzymes for various applications, highlighting its innovative microbial platforms.
Read more →-DYAI
May 19, 2026Dyadic Applied BioSolutions Announces Participation in Sidoti Virtual Investor Conference
Dyadic Applied BioSolutions will present at the Sidoti Virtual Investor Conference on May 20-21, 2026. Joe Hazelton, the company's President and COO, will lead the presentation, which can be accessed live. Additionally, Dyadic will offer virtual one-on-one meetings for investors, emphasizing their commitment to engagement and transparency.
Read more →-DYAI
May 13, 2026Dyadic Announces First Quarter 2026 Financial Results and Highlights Recent Company Progress
Dyadic International reported its Q1 2026 financial results, highlighting significant progress in commercializing animal-free recombinant proteins. The company has secured initial orders and launched new products, including AlbuFree™ DX. Despite a notable revenue increase of 182.3% year-over-year, Dyadic continues to face operational losses. The firm is expanding its collaborations and market presence, particularly in Europe and Asia.
Read more →-DYAI
May 13, 2026DYADIC ANNOUNCES FIRST QUARTER 2026 FINANCIAL RESULTS AND HIGHLIGHTS RECENT COMPANY PROGRESS Received initial purchase orders for recombinant bovine transferrin from customers in the cultivated meat industry Commercial l
Dyadic International, Inc. reported its financial results for Q1 2026, highlighting substantial revenue growth of 182.3% from the previous year. The company received initial orders for recombinant bovine transferrin from the cultivated meat sector and launched AlbuFree DX recombinant human albumin. Additionally, Dyadic expanded its collaborations with Fermbox Bio and entered agreements to distribute its recombinant products globally. Despite these advancements, the company noted a decrease in cash reserves compared to the previous quarter.
Read more →-DYAI
Apr 29, 2026▲ +8.2%on this news
Dyadic to Report Q1 2026 Financial Results and Host Conference Call on Wednesday May 13, 2026
Dyadic International, Inc. will report its Q1 2026 financial results on May 13, 2026, and host a conference call at 5:00 p.m. ET. The call will provide updates on the company's performance and future strategies. Investors can access the call via dial-in or webcast, with a replay available afterward.
Read more →-DYAI
Mar 25, 2026Dyadic Announces 2025 Financial Results and Highlights Recent Company Progress
Dyadic International, Inc. reported its 2025 financial results, highlighting significant corporate progress, including the commercial launch of AlbuFree™ DX and expanded collaborations with Fermbox Bio and IBT Bioservices. Despite a decrease in total revenue and an increase in net loss, the company is focused on accelerating the commercialization of animal-free proteins and enzymes. Dyadic's strategic partnerships and ongoing development projects aim to enhance its market presence across various sectors.
Read more →-DYAI
Mar 25, 2026DYADIC ANNOUNCES 2025 FINANCIAL RESULTS AND HIGHLIGHTS RECENT COMPANY PROGRESS Commercial launch of AlbuFree DX recombinant human albumin by Proliant Health & Biologicals using Dyadic's production platform, with Dyadic e
Dyadic International, Inc. has reported its 2025 financial results and highlighted significant achievements in its commercial and collaborative efforts. The successful launch of AlbuFree DX and expanded partnerships with Fermbox Bio, IBT Bioservices, and BRIG Bio mark key advances in Dyadic's strategy to enhance its market presence. However, the company experienced a revenue decline and a decrease in cash position, which could pose challenges moving forward. Dyadic aims to continue its focus on developing animal-free proteins and enzymes across various sectors.
Read more →-DYAI
Mar 16, 2026▲ +6.5%on this news
Dyadic Applied BioSolutions Announces Commercial Distribution Partnership with IBT Bioservices
Dyadic Applied BioSolutions has announced a commercial distribution partnership with IBT Bioservices, allowing Dyadic's recombinant protein products to be marketed through IBT's established sales channels. This agreement is a strategic move to transition from R&D-driven revenue to commercial product sales, enhancing market access and supporting ongoing revenue generation. The initial offerings will include recombinant DNase I and transferrin for research applications.
Read more →-DYAI
Mar 11, 2026Dyadic to Report 2025 Full Year Financial Results and Host Conference Call on Wednesday, March 25, 2026
Dyadic International, Inc. will report its financial results for the year ended December 31, 2025, and host a conference call on March 25, 2026. The call will provide updates on the company's performance and future strategies. Investors can participate by dialing in or accessing a webcast of the event.
Read more →-DYAI
Mar 4, 2026Dyadic and Fermbox Bio Launch First Product Under Expanded Collaboration: Animal-Origin-Free Recombinant DNase I (RNase-Free)
Dyadic Applied BioSolutions and Fermbox Bio have launched their first product, animal-origin-free Recombinant DNase I, under an expanded collaboration. This enzyme is designed for nucleic-acid clean-up and supports applications in biopharmaceutical manufacturing. The companies plan to introduce additional recombinant proteins throughout 2026, targeting high-demand segments in biotechnology and molecular diagnostics.
Read more →-DYAI
Mar 2, 2026Dyadic Applied BioSolutions and Inzymes ApS Announce Planned 2026 Commercialization of Non-Animal Dairy Enzyme Following Achievement of Development Milestone
Dyadic Applied BioSolutions and Inzymes ApS announced the planned commercialization of a non-animal dairy enzyme, recombinant bovine chymosin, in 2026. This follows the successful completion of development activities under their collaboration agreement. Dyadic received a $200,000 milestone payment and is positioned to earn royalties on future sales. The partnership aims to meet the growing demand for sustainable dairy processing solutions.
Read more →-DYAI
Feb 17, 2026Dyadic Applied BioSolutions and Proliant Health & Biologicals Announce Commercial Launch of Recombinant Human Albumin
Dyadic Applied BioSolutions and Proliant Health & Biologicals have launched AlbuFree™ DX, a recombinant human albumin product. This launch highlights Dyadic's commitment to producing animal-free proteins for life sciences. The partnership allows Dyadic to benefit from Proliant's established distribution network. The product is aimed at meeting the growing demand for scalable and supply-secure inputs in cell culture applications.
Read more →-DYAI
Feb 17, 2026Dyadic Applied BioSolutions and Proliant Health & Biologicals Announce Commercial Launch of Recombinant Human Albumin
Dyadic Applied BioSolutions and Proliant Health & Biologicals have launched AlbuFree™ DX, a recombinant human albumin product. This launch is part of Dyadic's strategy to focus on recombinant proteins with established commercial pathways. The collaboration allows Dyadic to benefit from Proliant's extensive distribution network and expertise in albumin production. The product aims to meet the growing demand for animal-free inputs in life sciences.
Read more →-DYAI
Dec 17, 2025Dyadic and Fermbox Bio Expand Strategic Collaboration to Accelerate Commercialization of Animal-Free Proteins and Enzymes Across Life Science, Food & Nutrition, and Bioindustrial Markets
Dyadic Applied BioSolutions has expanded its collaboration with Fermbox Bio to enhance the commercialization of animal-free proteins and enzymes. This partnership will allow Fermbox to manufacture Dyadic-developed products, leveraging both companies' strengths in microbial platforms. The agreement aims to accelerate product development and meet the growing demand for sustainable solutions in various markets.
Read more →-DYAI
Dec 15, 2025▼ -9.2%on this newsshared move
Dyadic Applied BioSolutions Establishes Commercial Partnership to Accelerate Adoption of Dyadic’s Recombinant Growth Factors and Media Proteins
Dyadic Applied BioSolutions has entered a commercial agreement with Opes Diagnostics to promote its recombinant protein products in serum-free cell culture media. The partnership aims to leverage Opes' market experience and relationships to enhance the adoption of Dyadic's offerings in Europe, Israel, and Asia. This collaboration marks a strategic shift for Dyadic towards broader commercial engagement.
Read more →-DYAI
Dec 1, 2025Dyadic and BRIG BIO Sign Development & Commercialization Agreement to Bring Animal-Free Bovine Alpha-Lactalbumin to Global Nutrition Markets
Dyadic Applied BioSolutions and BRIG BIO have signed a Development and Commercialization Agreement to produce animal-free bovine alpha-lactalbumin. This collaboration aims to enhance the scalability and affordability of alpha-lactalbumin for various nutrition markets. BRIG BIO will fund the development, while Dyadic will provide production strains and share in revenue. The global market for alpha-lactalbumin is expected to grow from approximately USD 760 million in 2025 to over USD 1.6 billion by 2035.
Read more →-DYAI
Nov 12, 2025Dyadic Announces Third Quarter 2025 Financial Results and Highlights Strategic Progress
Dyadic International, Inc. reported its Q3 2025 financial results, highlighting a strategic shift towards commercial operations under the new branding of Dyadic Applied BioSolutions. The company achieved significant milestones in recombinant protein programs and secured a CRISPR license to enhance production capabilities. Despite an increase in cash reserves, total revenue decreased compared to the previous year, and the company reported a higher net loss.
Read more →-DYAI
Nov 12, 2025Dyadic Announces Third Quarter 2025 Financial Results and Highlights Strategic Progress Completed strategic pivot from R&D focus to commercial focus Rebranded as Dyadic Applied BioSolutions and launched redesigned websit
Dyadic International, now rebranded as Dyadic Applied BioSolutions, reported positive financial results for Q3 2025, highlighting a successful transition to a commercially-focused biotechnology provider. The company has advanced various recombinant protein programs towards market readiness and received its first purchase order for cell culture media products. Additionally, Dyadic secured a CRISPR license from ERS Genomics, enhancing its genetic engineering capabilities. With a cash position of $10.4 million, Dyadic is positioned for sustainable growth and aims to tap into rising demand in biopharma markets, particularly in Asia.
Read more →-DYAI
Nov 10, 2025▲ +6.9%on this newsshared move
Dyadic Applied BioSolutions Expands Genetic Engineering Capabilities Through CRISPR/Cas9 Commercial License with ERS Genomics
Dyadic Applied BioSolutions has entered into a CRISPR/Cas9 licensing agreement with ERS Genomics, allowing access to their extensive patent portfolio. This collaboration aims to enhance Dyadic's capabilities in strain engineering and product optimization across its bioproduction platforms. The integration of CRISPR technology is expected to improve efficiency and adaptability in various sectors, including life sciences and bio-industrial applications.
Read more →-DYAI
Oct 30, 2025▲ +6.4%on this news
Dyadic Earnings
Dyadic International, Inc. will announce its financial results for the second quarter of 2025 on November 12, 2025. The company will also host a corporate update conference call to discuss these results. Dyadic specializes in producing high-value proteins for various applications using its proprietary gene expression platforms.
Read more →-DYAI
Oct 29, 2025Dyadic to Report Third Quarter 2025 Financial Results on Wednesday, November 12, 2025
Dyadic International, Inc. will report its financial results for Q2 2025 on November 12, 2025. The company will also host a conference call to discuss these results and provide a corporate update. Interested parties can access the call via dial-in numbers or a webcast link. Dyadic specializes in producing recombinant proteins for various markets.
Read more →-DYAI
Oct 6, 2025Dyadic Applied BioSolutions Announces Milestone Achievements and Recent Company Developments
Dyadic Applied BioSolutions has announced significant milestone achievements including a $500,000 payment from Proliant Health. The company is transitioning towards commercial focus, showcasing advancements in its collaborations with Proliant Health and Inzymes. Key developments include successful production of recombinant proteins for various markets, with future revenue growth anticipated as commercialization proceeds. However, the company faces uncertainties such as reliance on third-party partnerships and a history of net losses.
Read more →-DYAI
Sep 4, 2025Dyadic to Present at Investor Conferences and BPI East
Dyadic International, Inc. announced its participation in several upcoming investor conferences, including the H.C. Wainwright 27th Annual Global Investment Conference and BioProcess International BPI East. Joe Hazelton, the President & COO, will represent the company, highlighting its focus on scalable production of functional input proteins. Dyadic aims to connect with investors and industry partners during these events.
Read more →-DYAI
Aug 13, 2025Dyadic Reports Second Quarter 2025 Financial Results and Highlights of Recent Company Progress
Dyadic International reported its financial results for Q2 2025, showcasing a strategic shift from R&D to commercial operations. The company, now rebranded as Dyadic Applied BioSolutions, highlighted key milestones in life sciences and nutrition, alongside a successful $5.3 million equity offering. The advancements in recombinant protein programs are expected to drive future revenue growth.
Read more →-DYAI
Aug 13, 2025Dyadic Reports Second Quarter 2025 Financial Results and Highlights of Recent Company Progress Completed Strategic Leadership and Operational Transformation from R&D to Commercial Operations Rebranded as Dyadic Applied B
Dyadic International, Inc. reported its financial results for the second quarter of 2025, highlighting significant progress in its transformation to a commercially oriented biotech company. The company successfully completed a $5.3 million equity offering to bolster its liquidity and fund ongoing pipeline growth. Dyadic's rebranding effort reflects a shift towards commercial execution, with several recombinant protein programs nearing commercialization. Despite increases in R&D expenses, the company achieved key milestones and recorded substantial revenue growth compared to the previous year.
Read more →-DYAI
Aug 5, 2025Dyadic to Report Second Quarter 2025 Financial Results on Wednesday, August 13, 2025
Dyadic International, Inc. will announce its second quarter 2025 financial results on August 13, 2025. The company will also host a corporate update conference call at 5:00 p.m. Eastern Time. Interested parties can access the live event via a webcast link, and a recording will be available afterward.
Read more →-DYAI
Jul 31, 2025UPDATE: Dyadic International, Inc. Announces Pricing of Public Offering of 6,052,000 Shares of Common Stock
Dyadic International, Inc. has announced the pricing of a public offering of 6,052,000 shares of common stock at $0.95 per share, aiming to raise about $5.75 million. The offering is expected to close on August 1, 2025, and proceeds will be used for working capital and corporate purposes. Craig-Hallum Capital Group LLC is the sole managing underwriter for this offering.
Read more →-DYAI
Jul 30, 2025Dyadic International, Inc. Announces Proposed Public Offering of Common Stock
Dyadic International, Inc. has announced a proposed public offering of common stock as of July 30, 2025. The company aims to utilize the proceeds for working capital and general corporate activities, including product development and sales. The offering is underwritten by Capital Group LLC, but its completion is subject to market conditions and other uncertainties. Additionally, the size and terms of the offering remain undefined, indicating potential risks for investors.
Read more →-DYAI
Jul 2, 2025Dyadic International, Inc. Announces Strategic Rebrand to Dyadic Applied BioSolutions
Dyadic International, Inc. has announced a strategic rebranding to Dyadic Applied BioSolutions, emphasizing its focus on commercializing non-therapeutic proteins. This shift aims to enhance revenue potential and market reach through its proprietary gene expression platforms. The company has achieved significant milestones, including funding for developing low-cost monoclonal antibodies, and is on track to commercialize its products by 2025.
Read more →-DYAI
Jun 2, 2025Dyadic Announces Leadership Change as Part of Ongoing Strategic Shift to Focus on High Demand Ancillary Proteins for Life Sciences, Nutrition, and Industrial Applications
Dyadic International has announced a leadership change, appointing Joe Hazelton as President to drive its strategic shift towards ancillary recombinant protein products. This move is aimed at enhancing commercialization in high-demand markets such as life sciences and nutrition. The company has already validated its strategy through significant partnerships and is focusing on scaling operations.
Read more →-DYAI
May 14, 2025Dyadic Reports First Quarter 2025 Financial Results and Highlights of Recent Company Progress
Dyadic International, Inc. reported its Q1 2025 financial results, highlighting significant advancements in its life science and industrial product portfolio. The company secured a $4.5 million grant from CEPI and launched research initiatives funded by the Gates Foundation. Dyadic is focused on commercializing its proprietary protein production platforms, aiming for sustainable growth in high-demand sectors.
Read more →-DYAI
May 1, 2025Dyadic to Report First Quarter 2025 Financial Results on Wednesday, May 14, 2025
Dyadic International, Inc. will report its first quarter 2025 financial results on May 14, 2025. The company will also host a corporate update conference call at 5:00 p.m. ET. Interested parties can access the call through a provided dial-in number or webcast link. Dyadic specializes in large-scale protein manufacturing for various applications.
Read more →-DYAI
Apr 16, 2025Dyadic to Present at World Vaccine Congress | Washington
Dyadic International, Inc. announced that CEO Mark Emalfarb will present at the 2025 World Vaccine Congress in Washington, D.C. on April 23, 2025. The presentation will focus on the C1 platform's ability to produce non-mRNA antigens for vaccines, particularly in response to avian influenza and future pandemics. Dyadic aims to enhance biomanufacturing efficiency and meet global health demands.
Read more →-DYAI
Mar 26, 2025Dyadic Reports 2024 Year-End Financial Results and Business Updates
Dyadic International reported its 2024 financial results, highlighting a strong revenue performance of approximately $3.5 million, driven by milestone revenues. The company received significant grants aimed at accelerating its C1 platform for vaccine development. Dyadic is advancing multiple products towards market launch and expanding its alternative protein portfolio, despite reporting a net loss of $5.8 million.
Read more →-DYAI
Mar 20, 2025▼ -6%on this news
Dyadic Announces Funding Award from CEPI to Use C1 to Accelerate Development of Protein-Based Vaccines
Dyadic International has received a $4.5 million funding award from CEPI to utilize its C1 technology for the accelerated development of protein-based vaccines. This funding aims to explore the efficiency of producing antigens using C1 filamentous fungus, which could significantly shorten the vaccine production timeline from months to just 35 days. The project aligns with CEPI's goal to enhance pandemic preparedness and improve global vaccine access.
Read more →-DYAI
Mar 12, 2025Dyadic to Report 2024 Full Year Financial Results and Host Conference call on Wednesday, March 26, 2025
Dyadic International, Inc. announced it will report its financial results for the year 2024 and host a corporate update conference call on March 26, 2025. The call will provide an opportunity for stakeholders to engage with management and ask questions. Dyadic specializes in large-scale protein manufacturing for various applications, including vaccines and therapeutics.
Read more →-DYAI
Mar 6, 2025Dyadic to Attend Multiple Industry Events in March
Dyadic International, Inc. announced its participation in several key industry events in March 2025, including the World AGRI-Tech Innovation Summit and Future Food-Tech in San Francisco, as well as Microbial Engineering III in Porto, Portugal. The company aims to showcase its advanced protein production platforms, which are applicable in both pharmaceutical and non-pharmaceutical sectors. This engagement reflects Dyadic's commitment to innovation in biotechnology.
Read more →-DYAI
Jan 6, 2025▲ +6.5%on this news
Dyadic Provides Business Update; Dyadic to Attend the 43rd Annual J.P. Morgan Healthcare Conference
Dyadic International, Inc. provided a business update highlighting its focus on alternative proteins and its attendance at the upcoming J.P. Morgan Healthcare Conference. The company is advancing its C1 protein production platform for vaccines and diagnostics, with significant partnerships and a $3 million grant from the Gates Foundation. Key product launches are anticipated in 2025.
Read more →-DYAI
Nov 21, 2024▲ +12.1%on this news· ran to +30% by day 1
Dyadic Receives $3 Million Grant to Develop Cost-Effective Monoclonal Antibodies for RSV and Malaria Using C1 Platform Technology
Dyadic International has secured a $3 million grant from the Gates Foundation to enhance its C1 protein production platform for developing monoclonal antibodies targeting RSV and malaria. This initiative aims to provide affordable treatment options for underserved populations, particularly in low-income countries. The funding will support the rapid and cost-effective production of high-quality mAbs, addressing significant global health challenges.
Read more →-DYAI
Nov 12, 2024Dyadic Announces Third Quarter 2024 Financial Results and Strategic Progress Across Key Markets
Dyadic International reported a significant revenue increase for Q3 2024, primarily due to licensing fees and milestone payments. The company has expanded its partnerships in alternative proteins and human health, including a collaboration for a monkeypox vaccine. With a strong cash position, Dyadic is well-positioned for future growth across multiple markets.
Read more →-DYAI
Nov 4, 2024Dyadic to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024
Dyadic International, Inc. will announce its financial results for Q3 2024 on November 12, 2024. The company specializes in large-scale protein manufacturing for vaccines and therapeutics. A conference call will follow the announcement, providing an opportunity for stakeholders to engage with management. The event will be accessible via a webcast.
Read more →-DYAI
Oct 9, 2024Dyadic Expands Global Presence with Participation in Key Industry Events
Dyadic International, Inc. has announced its participation in several major industry events, including the DCVMN Annual Meeting and the World Vaccine Congress Europe. These engagements aim to promote its innovative C1 and Dapibus™ technology platforms for efficient protein production. Dyadic seeks to expand its global presence and foster collaborations in the biomanufacturing sector.
Read more →-DYAI
Sep 23, 2024Dyadic Provides Alternative Proteins Business Update and Announces Attendance at Bioprocess International Conference
Dyadic International, Inc. has provided a business update and announced its participation in the Bioprocess International Conference in Boston. The company is focusing on its C1 and Dapibus™ platforms for efficient protein manufacturing. Recent developments include partnerships for animal-free recombinant albumin and ongoing projects for various proteins with potential applications in pharmaceuticals and nutrition.
Read more →-DYAI
Aug 13, 2024Dyadic Announces Second Quarter 2024 Financial Results and Highlights Recent Company Progress
Dyadic International, Inc. announced its second quarter 2024 financial results, highlighting significant progress in partnerships and product development. The company entered agreements for animal-free recombinant albumin and non-animal alpha-lactalbumin, while also advancing its vaccine candidates against avian influenza. Despite a decrease in revenue, Dyadic's cash position improved, reflecting a strategic focus on commercialization.
Read more →-DYAI
Jul 30, 2024Dyadic to Report Second Quarter 2024 Financial Results on Tuesday, August 13, 2024
Dyadic International, Inc. has announced it will report its financial results for the second quarter of 2024 on August 13, 2024. The company will also host a corporate update conference call at 5:00 p.m. Eastern Time. Investors can access the call via dial-in numbers or a webcast link provided in the announcement.
Read more →-DYAI
Jun 28, 2024▼ -9.8%on this news
Dyadic International, Inc. and Proliant Health and Biologicals announce Recombinant Albumin Development and Commercialization Partnership
Dyadic International has partnered with Proliant Health and Biologicals to develop and commercialize animal-free recombinant albumin products. The agreement includes a $1.5 million upfront payment and a share of profits from sales. The partnership targets the growing serum albumin market, with the first product expected to launch in early 2025.
Read more →-DYAI
May 30, 2024Dyadic to Attend Industry Events in June
Dyadic International, Inc. announced its participation in several industry events in June 2024, including BIO 2024 and Future Food Tech. The company aims to showcase its protein production technologies and engage with potential partners. Dyadic focuses on manufacturing proteins for vaccines and therapeutics, leveraging its proprietary platforms.
Read more →-DYAI
May 14, 2024▲ +5.4%on this news
Dyadic Announces First Quarter 2024 Financial Results and Highlights Recent Company Progress
Dyadic International, Inc. reported its Q1 2024 financial results, highlighting significant advancements in its vaccine and protein production platforms. The company successfully completed a Phase 1 clinical trial for its DYAI-100 COVID-19 vaccine candidate, demonstrating safety and immune response. Additionally, Dyadic has entered into multiple partnerships with leading pharmaceutical firms and expanded its research collaborations. Despite a rise in net loss, the company remains optimistic about its future prospects and ongoing projects.
Read more →-DYAI
May 8, 2024Dyadic to Attend Industry and Investor Events in May
Dyadic International, Inc. announced its participation in several industry and investor events throughout May 2024. These events include PEGS Boston, the EFHutton Annual Global Conference, and the ECI Vaccine Technology IX. The company aims to showcase its microbial platforms for bioproduction and its lead asset, the DYAI-100 COVID-19 vaccine candidate.
Read more →-DYAI
Apr 30, 2024Dyadic to Report First Quarter 2024 Financial Results on Tuesday, May 14, 2024
Dyadic International, Inc. announced it will report its financial results for Q1 2024 on May 14, 2024. The company will also host a corporate update conference call at 5:00 p.m. Eastern Time. Interested parties can access the call via a provided webcast link and submit questions in advance.
Read more →-DYAI
Mar 28, 2024Dyadic Reports 2023 Full Year Results and Recent Company Progress
Dyadic International, Inc. reported its financial results for 2023, highlighting significant progress, including the successful Phase 1 trial of its DYAI-100 COVID-19 vaccine candidate. The company secured $6 million in convertible notes and entered several partnerships for vaccine development. Despite a net loss of $6.8 million, Dyadic remains committed to advancing its microbial platforms for various applications.
Read more →-DYAI
Mar 28, 2024Dyadic Announces Change in Board and Management Leadership Roles
Dyadic International has announced significant changes in its leadership, with Patrick Lucy succeeding Michael Tarnok as Chairman of the Board and Joseph Hazelton appointed as Chief Operating Officer. Tarnok will remain on the Board until June 2025, while Dr. Barry Buckland is retiring. The company aims to leverage its C1 and Dapibus platforms for growth in both pharmaceutical and non-pharmaceutical applications.
Read more →-DYAI
Mar 27, 2024Dyadic to Attend Industry Events in April
Dyadic International, Inc. announced its participation in two significant industry events in April 2024. The company will present its innovative vaccine development platform at the World Vaccine Congress and will also attend The Future of Protein Production conference. These events highlight Dyadic's commitment to advancing biopharmaceutical products for health and wellness.
Read more →-DYAI
Mar 26, 2024Dyadic Announces Publication of C1 Monoclonal Antibody in Nonhuman Primate Study in Nature Communications
Dyadic International announced the publication of a study demonstrating that its C1 produced monoclonal antibody offers protection against SARS-CoV-2 in both hamster and nonhuman primate models. The findings suggest that the C1-expression system is a promising platform for developing human monoclonal antibodies. The study emphasizes the potential for rapid production and adaptability to emerging virus variants, enhancing global health preparedness.
Read more →-DYAI
Mar 21, 2024Dyadic to Attend Future Food Tech Event March 21 – 22, 2024 in San Francisco, California
Dyadic International, Inc. announced its participation in the Future Food-Tech event on March 21-22, 2024, in San Francisco. The company will showcase its Dapibus™ Microbial Expression System and discuss advancements in its alternative proteins business. Additionally, Dyadic has formed a co-marketing partnership with Biftek, Inc. to promote a cost-effective growth medium supplement.
Read more →-DYAI
Mar 14, 2024Dyadic to Report Full Year 2023 Financial Results and Host Conference call on Thursday, March 28, 2024
Dyadic International, Inc. will report its financial results for the year ended 2023 and host a corporate update conference call on March 28, 2024. The call will provide insights into the company's advancements in microbial protein production platforms and its commitment to developing biopharmaceutical products. Interested parties can access the call via dial-in or webcast.
Read more →-DYAI
Mar 11, 2024CORRECTION – Dyadic Announces Closing of Private Placement of $6.0 Million Convertible Notes to Accelerate Near-Term Revenue Growth and Commercialization
Dyadic International, Inc. has closed a private placement of $6.0 million in convertible notes to support its growth and commercialization efforts. The funding will help propel revenue growth and enhance shareholder value through collaborations and product development. The company has seen increased interest in its technologies following positive clinical trial results.
Read more →-DYAI
Mar 1, 2024Dyadic to Attend Industry Events in March
Dyadic International, Inc. will attend several industry events in March 2024, including BIO-Europe Spring in Barcelona and the Vaccine Innovation Forum in Shanghai. The company's focus is on advancing its microbial platforms for bioproduction and addressing unmet clinical needs. Dyadic aims to facilitate the development of effective biopharmaceutical products and vaccines.
Read more →-DYAI
Feb 28, 2024Dyadic Announces Strategic Partnership Agreement to Develop Affordable Rabies Prophylactics and Vaccines Using its Proprietary C1 Cell Microbial Protein Production Platform
Dyadic International has entered a strategic partnership with Rabian BV to develop affordable rabies vaccines using its C1 protein production platform. The collaboration, supported by approximately €1.7 million in funding, aims to tackle the global rabies burden, particularly in lower- and middle-income countries. Dyadic will receive equity and royalties upon commercialization.
Read more →-DYAI
Feb 21, 2024▲ +11.9%on this news
Dyadic Advances Collaboration with Israel Institute for Biological Research (IIBR) Targeting Bio-Threats and Emerging Disease Solutions
Dyadic International has advanced its collaboration with the Israel Institute for Biological Research to develop solutions for emerging diseases and bio-threats. This partnership leverages Dyadic's microbial platforms and IIBR's discovery capabilities to create effective vaccines and treatments. The collaboration aims to enhance the speed and affordability of biomanufacturing, with future commercialization planned through out-licensing initiatives.
Read more →-DYAI
Feb 13, 2024Dyadic and Cygnus Technologies Announce Partnership To Provide C1 HCP ELISA Assay to Enhance Quality Assurance in Biomanufacturing
Dyadic International Inc. has partnered with Cygnus Technologies to launch the C1 HCP ELISA Kit, aimed at improving quality assurance in biomanufacturing. This kit will help quantify Host Cell Proteins, which are crucial for ensuring drug efficacy and safety. The collaboration is expected to facilitate broader adoption of Dyadic's C1 protein production platform, enhancing healthcare access globally.
Read more →-DYAI
Feb 6, 2024Dyadic Announces Research and Development Collaboration Agreement with Global Biopharmaceutical Company
Dyadic International has entered a fully funded evaluation agreement with a major biopharmaceutical company to utilize its C1 microbial protein production platform. This collaboration aims to design and produce recombinant proteins, with funding provided by the collaborator. The CEO highlighted the growing interest in their C1 technology following positive Phase I results for a recombinant vaccine.
Read more →-DYAI
Feb 1, 2024▲ +6.2%on this newsshared move
Dyadic to Attend BIO CEO & Investor Conference and European Industry Events
Dyadic International, Inc. announced its participation in several upcoming industry events in February 2024, including the BIO CEO & Investor Conference. The company is dedicated to developing innovative microbial platforms to meet the global demand for biopharmaceutical products and alternative proteins. Their lead asset includes the DYAI-100 COVID-19 vaccine candidate.
Read more →-DYAI
Jan 2, 2024Dyadic to Attend J.P. Morgan 42nd Annual Healthcare Conference
Dyadic International, Inc. will attend the J.P. Morgan 42nd Annual Healthcare Conference in January 2024. The company aims to address global protein bioproduction and unmet clinical needs through its innovative microbial platforms. CEO Mark Emalfarb and CBO Joe Hazelton will be available for meetings during the event.
Read more →-DYAI
Nov 30, 2023Dyadic Attends Investor Events in December
Dyadic International, Inc. announced its participation in two investor events in December 2023, including NobleCon-19 and The Benchmark Company's Investor Conference. CEO Mark Emalfarb will present at NobleCon-19 on December 5. The company focuses on innovative microbial platforms for bioproduction and aims to address unmet clinical needs.
Read more →-DYAI
Nov 29, 2023Dyadic Announces Top-Line Results from its Successful Phase 1 Clinical Trial for a First-in-Human Filamentous Fungal-Based Vaccine Candidate
Dyadic International, Inc. announced successful top-line results from its Phase 1 clinical trial of the DYAI-100 vaccine candidate, demonstrating safety and reactogenicity. Conducted with 30 healthy adults, the trial confirmed that both dose levels were well-tolerated with no serious adverse events. The results mark a significant milestone for Dyadic's C1-cell expression platform in vaccine development.
Read more →-DYAI
Nov 20, 2023▲ +5.8%on this news
Dyadic’s C1 Platform to be Used to Produce Vaccines for Humans and Animals in Africa
Dyadic International has announced a partnership with Rubic One Health and Afreximaxbank to establish a vaccine manufacturing facility in South Africa. This initiative aims to produce affordable vaccines for both humans and animals across Africa, addressing the continent's significant vaccine inequity. The collaboration will leverage Dyadic's C1 protein production platform to enhance local vaccine accessibility and affordability.
Read more →-DYAI
Nov 8, 2023Dyadic Announces Third Quarter 2023 Financial Results and Highlights Recent Company Progress
Dyadic International, Inc. reported its third quarter 2023 financial results, highlighting significant advancements in its product pipeline and collaborations. The company received an upfront payment of $0.6 million for its Dapibus™ platform and anticipates top-line results from its DYAI-100 Phase 1 clinical trial by December 2023. Despite a decrease in research revenue and a net loss, Dyadic's strategic partnerships and expanded leadership signal positive growth prospects.
Read more →-DYAI
Oct 30, 2023▲ +8.1%on this news
Dyadic to Present at Industry Events in November
Dyadic International, Inc. announced its participation in several industry events in November 2023. Key presentations will focus on advancements in vaccine development and protein production technologies. The events include the Cultured Meat Symposium and the Vaccines Summit, where Dyadic aims to showcase its innovative microbial platforms. Management will be available for one-on-one meetings at these events.
Read more →-DYAI
Oct 25, 2023Dyadic to Report Third Quarter 2023 Financial Results on Wednesday, November 8, 2023
Dyadic International, Inc. will report its third quarter 2023 financial results on November 8, 2023. The company will also host a corporate update conference call at 5:00 p.m. ET. Dyadic focuses on innovative microbial platforms for biopharmaceuticals and alternative proteins, aiming to meet global demands in health and nutrition.
Read more →-DYAI
Oct 9, 2023Dyadic Appoints Doug Pace to Its Executive Leadership Team
Dyadic International has appointed Doug Pace as Executive Vice President of Business Development to enhance its leadership team. This move comes in response to growing interest in Dyadic's microbial platforms, particularly the C1 technology for vaccines and the Dapibus™ platform for nutritional applications. Pace's extensive experience in biopharmaceuticals is expected to bolster the company's growth and strategic initiatives.
Read more →-DYAI
Oct 5, 2023▼ -9.8%on this newsshared move
Dyadic’s C1 Platform Selected by the Vaccine and Immunotherapy Center (“VIC”) at Massachusetts General Hospital as Part of VIC’s $5.88 Million Award by U.S. DoD to Develop a Self-Assembling Vaccine (SAV) Platform for Rapid Production of Prophylactic Vaccines for Infectious Diseases
Dyadic International has partnered with the Vaccine and Immunotherapy Center at Massachusetts General Hospital to utilize its C1 protein production platform for developing a Self-Assembling Vaccine (SAV) platform. This collaboration is part of a $5.88 million grant from the U.S. Department of Defense aimed at creating rapid production methods for vaccines against infectious diseases. The SAV platform is expected to enhance vaccine efficacy and speed of development.
Read more →-DYAI
Sep 29, 2023Dyadic to Present at Industry and Investor Events in October
Dyadic International, Inc. announced its participation in several industry and investor events throughout October 2023. Key presentations will focus on advancements in protein production and vaccine development, highlighting the company's innovative microbial platforms. Notable events include the Enzyme Engineering XXVII and World Vaccine Congress Europe, where management will discuss their technologies and contributions to global health.
Read more →-DYAI
Sep 26, 2023▼ -9.5%on this newsshared move
Dyadic and bYoRNA Announce a Collaboration Targeting the Production of Abundant, Low-Cost mRNA From C1-Cells
Dyadic International and bYoRNA SAS have formed a collaboration to develop cost-effective mRNA production technologies. This partnership aims to leverage Dyadic's C1 protein production platform to manufacture high-quality mRNA, making it more accessible, especially in emerging markets. The global mRNA market is projected to grow significantly, presenting a valuable opportunity for both companies.
Read more →-DYAI
Sep 19, 2023Dyadic Announces Development and License Agreement to Commercialize Animal-Free Alternative Proteins Using Dapibus™
Dyadic International has entered a development and licensing agreement to commercialize animal-free dairy enzymes using its Dapibus™ platform. The agreement includes an upfront payment of $0.6 million, with additional potential fees and royalties. This move positions Dyadic to capitalize on the growing demand for alternative proteins, with the market projected to exceed $190 billion by 2028.
Read more →-DYAI
Sep 12, 2023Dyadic to Present at BioProcess International
Dyadic International, Inc. announced that Joseph Hazelton, the Chief Business Officer, will present at BioProcess International from September 19-21, 2023. The presentation will focus on their C1 Gene Expression Platform, which aims to enhance the development and manufacturing of biologics. Dyadic is committed to addressing global protein production needs and advancing its pipeline of biologic products.
Read more →-DYAI
Aug 9, 2023▲ +10%on this news
Dyadic Announces Second Quarter 2023 Financial Results and Highlights Recent Company Progress
Dyadic International, Inc. reported positive interim results from its Phase 1 clinical trial for the DYAI-100 vaccine candidate, showing no major safety concerns. The company has expanded its collaborations with top pharmaceutical firms and is making progress in developing animal-free proteins. Despite a net loss of $2.15 million, Dyadic maintains a strong cash position.
Read more →-DYAI
Aug 7, 2023Dyadic Announces Continued Progress Towards Commercialization of Animal-Free Recombinant Serum Albumin
Dyadic International has announced promising results from third-party testing of its animal-free recombinant serum albumin, demonstrating structural equivalence to commercial products. The company is leveraging its microbial protein production platforms to meet the growing demand in the global serum albumin market, projected to reach $8.2 billion by 2028. This development positions Dyadic favorably for commercialization opportunities in both pharmaceutical and non-pharmaceutical applications.
Read more →-DYAI
Jul 26, 2023Dyadic to Report Second Quarter 2023 Financial Results on Wednesday, August 9, 2023
Dyadic International, Inc. will report its second quarter 2023 financial results on August 9, 2023. The company focuses on innovative microbial platforms for protein bioproduction and aims to address unmet clinical needs. A conference call will be held to discuss the results, with details provided for participation.
Read more →-DYAI
Jul 24, 2023Dyadic Provides Phase 1 Clinical Trial Update for its Recombinant Protein RBD Vaccine Candidate
Dyadic International has completed dosing for its Phase 1 clinical trial of the DYAI-100 COVID-19 vaccine. An interim analysis by the Data Safety Monitoring Board revealed no major safety concerns and confirmed an immune response at both low and high doses. The full study report is anticipated in Q4 2023.
Read more →-DYAI
Oct 12, 2020Document Dyadic Updates Market on COVID-19 Initiatives C1 Expression of SARS-CoV-2 Monoclonal Antibody Achieved Ten On-going Animal Trials of C1 Expressed SARS-CoV-2 Receptor Binding Domain (RBD) Antigen by Seven Differe
Dyadic Updates Market on COVID-19 Initiatives C1 Expression of SARS-CoV-2 Monoclonal Antibody Achieved Ten On-going Animal Trials of C1 Expressed SARS-CoV-2 Receptor Binding Domain (RBD) Antigen by Seven Different Collaborators Record Expression Level of C1 SARS-CoV-2 RBD Anti
Read more →-DYAI
Mar 18, 2020Document Dyadic Presents New Business Opportunities to Address COVID-19, Influenza and Continued Scientific and Business Development Progress JUPITER
Dyadic Presents New Business Opportunities to Address COVID-19, Influenza and Continued Scientific and Business Development Progress JUPITER, FLORIDA ACCESSWIRE March 18, 2020 - Dyadic International, Inc. ("Dyadic" or the Company ) (NASDAQ DYAI), a global biotechnology company
Read more →-DYAI
Feb 25, 2020Document Dyadic and The Israel Institute for Biological Research (IIBR) Expand Collaboration to Combat Emerging Diseases Nes - Ziona, ISRAEL and JUPITER
Dyadic and The Israel Institute for Biological Research (IIBR) Expand Collaboration to Combat Emerging Diseases Nes - Ziona, ISRAEL and JUPITER, FL ACCESSWIRE February 25, 2020 Dyadic International, Inc. (''Dyadic'') (NASDAQ DYAI), a global biotechnology company announced today
Read more →-DYAI
Feb 21, 2020Document DYADIC ANNOUNCES NEW MILESTONE AS G2 HUMAN LIKE GLYCOSYLATION REACHED - Further Extends Company's Biologic Market Opportunities - JUPITER
DYADIC ANNOUNCES NEW MILESTONE AS G2 HUMAN LIKE GLYCOSYLATION REACHED -Further Extends Company's Biologic Market Opportunities - JUPITER, FL ACCESSWIRE February 21, 2020 Dyadic International, Inc. ("Dyadic") (NASDAQ DYAI), a global biotechnology company focused on further impr
Read more →-DYAI
Jan 27, 2020Document Dyadic to Interview with FOX Business Network on Monday
Dyadic to Interview with FOX Business Network on Monday, January 27, 2020 JUPITER, FLORIDA ACCESSWIRE January 27, 2020 - Dyadic International, Inc. ("Dyadic" or the Company ) (NASDAQ DYAI), a global biotechnology company focused on further improving and applying its proprietary
Read more →-DYAI
Jan 6, 2020Document Dyadic Reports Continued Positive Business Trends and Scientific Results in Fourth Quarter 2019 Expanded ZAPI Program and Positive Preliminary Results from ZAPI Animal Study New Collaboration Agreement with Top
Dyadic Reports Continued Positive Business Trends and Scientific Results in Fourth Quarter 2019 Expanded ZAPI Program and Positive Preliminary Results from ZAPI Animal Study New Collaboration Agreement with Top Ten Pharmaceutical Company Expanded Research Relationship with Le
Read more →-DYAI
Nov 25, 2019Document DYADIC ANNOUNCES ACHIEVING HUMAN LIKE GLYCAN STRUCTURES FROM ITS ENGINEERED C1 CELL LINE - High G0 Glycosylation Level Driving Program Acceleration - JUPITER
DYADIC ANNOUNCES ACHIEVING HUMAN LIKE GLYCAN STRUCTURES FROM ITS ENGINEERED C1 CELL LINE - High G0 Glycosylation Level Driving Program Acceleration - JUPITER, FL ACCESSWIRE November 25, 2019 Dyadic International, Inc. ("Dyadic") (NASDAQ DYAI), a global biotechnology company fo
Read more →-DYAI
Feb 13, 2019Dyadic Announces Effectiveness of Form 10 Registration Statement and Application to NASDAQ Jupiter, FL / ACCESSWIRE /
Dyadic Announces Effectiveness of Form 10 Registration Statement and Application to NASDAQ Jupiter, FL / ACCESSWIRE / February 13, 2019 / Dyadic International, Inc. (the "Company") (OTCQX: DYAI) today announced that the Securities and Exchange Commission (the "SEC") has declare
Read more →-DYAI
Nov 17, 2008Codexis, Dyadic In Enzyme Production System License Agreement Redwood City, CA and Jupiter, FL
Codexis, Dyadic In Enzyme Production System License Agreement Redwood City, CA and Jupiter, FL Codexis, Inc. and Dyadic International (USA), Inc. today announced a license agreement covering use of Dyadic's C1 expression system for large-scale production of enzymes in certain f
Read more →-DYAI
Jun 19, 2008Harry Z. Rosengart Notifies Dyadic International, Inc. of His Resignation
Z. Rosengart Notifies Dyadic International, Inc. of His Resignation Fla. - June 19, 2008 - Dyadic International, Inc. (the "Company") announced today that, on June 13, 2008, Harry Z. Rosengart notified the Company of his resignation (i) as the Chairman of the Board of Director
Read more →-DYAI
Jun 5, 2008Dyadic's Executive Officers and Key Employees Announce Their Resignation
Executive Officers and Key Employees Announce Their Resignation Fla. - June 5, 2008 - Dyadic International, Inc. (the "Company") announced today that, on May 30, 2008, the Company received notice from all of its executive officers and certain key employees of their resignation
Read more →-DYAI
May 13, 2008DYADIC INTERNATIONAL, INC. 140 Intracoastal Pointe Drive, Suite 404 Jupiter, FL 33477 NOTICE OF ANNUAL MEETING OF STOCKHOLD ERS TO BE HELD ON FRIDAY, JUNE 20, 2008, AT 10:00 A.M. To the stockholders of Dyadic Internation
Intracoastal Pointe Drive, Suite 404 ANNUAL MEETING OF STOCKHOLDERS BE HELD ON FRIDAY, JUNE 20, 2008, AT 10:00 A.M. stockholders of Dyadic International, Inc.: meeting of stockholders of Dyadic International, Inc., a Delaware corporation, will be held on Friday, June 20, 200
Read more →-DYAI
Apr 15, 2008GRANTED EFiled: Apr 15 2008 9:57AM EDT Transaction ID 19406728 Case No. 3353-VCP IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE MARK A. EMALFARB, Plaintiff, v. DYADIC INTERNATIONAL, INC., Defendant. ) ) ) ) ) ) ) ) )
THE COURT OF CHANCERY OF THE STATE OF DELAWARE plaintiff Mark A. Emalfarb ("Plaintiff") brought this action pursuant to 8 Del. C. 211 to compel defendant Dyadic International, Inc. ("Defendant," or the "Company") to hold an annual meeting of the Company's stockholders for the
Read more →-DYAI
Mar 14, 2008Dyadic International, Inc. Announces Changes to its Board of Directors
International, Inc. Announces Changes to its Board of Directors Fla - March 14, 2008 - Dyadic International, Inc. (the "Company") today announced the election of Mr. Wendell H. Adair, Jr., to the Board of Directors (the "Board") of the Company. Mr. Adair replaces Mr. Richard J
Read more →-DYAI
Mar 4, 2008REPORT OF INTERNAL INVESTIGATION TO THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS OF DYADIC INTERNATIONAL, INC. Submitted by: Moscowitz & Moscowitz, P.A. 1111 Brickell Avenue, Suite 2050 Miami, FL 33131 Phone: (305) 379-
INTERNAL INVESTIGATION Brickell Avenue, Suite 2050 Page I. Independence and Scope of the Investigation 3 II. Background Information 3 III. The Course of the Investigation 9 A. Interviews 9 B. Dyadic document reviews 11 C. Auditor document reviews 11 D. Computer forensics 11 IV
Read more →-DYAI
Jan 18, 2008Dyadic Affirms Ownership of All Intellectual Property Underlying its Technologies and Provides Other Updates
Affirms Ownership of All Intellectual Property Underlying its Technologies Provides Other Updates Fla - January 18, 2008 - Dyadic International, Inc. (the "Company") announced today that as previously disclosed in the Company's Current Reports on (filed on December 3, 2007 an
Read more →-DYAI
Jan 2, 2008LEVIN GINSBURG 80 North LaSalle Street w Suite 3200 Attorneys at Law Chicago, Illinois 60601-2800 312.368.0100
Overnight Courier, Email and Telefax No. 561-743-8343 International (USA), Inc. known as Dyadic International, Inc. Intracoastal Pointe Drive, Suite 404 Wayne Moor, Chief Executive Officer, President and Board Member Default under Revolving Note ($3,000,000.00) may recall,
Read more →-DYAI
Dec 28, 2007IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE IN AND FOR NEW CASTLE COUNTY MARK A. EMALFARB, Plaintiff, v. DYADIC INTERNATIONAL, INC., Defendant . ) ) ) ) ) ) ) ) ) ) Civil Action No. ______________ VERIFIED COMPLAIN
COURT OF CHANCERY OF THE STATE OF DELAWARE FOR NEW CASTLE COUNTY ("Emalfarb"), by and through his undersigned counsel, brings this action pursuant to 8 Del.C. setting a date for an annual meeting of stockholders of Dyadic International, Inc. ("Dyadic" or the "Company"), and
Read more →-DYAI
Dec 3, 2007Dyadic Receives Delisting Notice from American Stock Exchange and Provides Updates Regarding Gordian Strategic Process and Other Events Company Appeals Amex Decision
Receives Delisting Notice from American Stock Exchange and Provides Updates Regarding Gordian Strategic Process and Other Events Appeals Amex Decision Fla - December 3, 2007 - Dyadic International, Inc. (AMEX: DIL) announced that it has received notice from the Listing Qualif
Read more →-DYAI
Nov 19, 2007Dyadic Provides Strategic and Business Update
Provides Strategic and Business Update Fla - November 19, 2007 - Dyadic International, Inc. (AMEX: DIL) announced that it has made progress in the Gordian Group-assisted value maximization process and has taken steps to ensure that the Company is not disrupted during previous
Read more →-DYAI
Oct 3, 2007LEVIN GINSBURG 180 North LaSalle Street, Suite 3200 Attorneys at Law Chicago, Illinois 60601-2800 312.368.0100
LaSalle Street, Suite 3200 Overnight Courier and Regular Mail International (USA), Inc. known as Dyadic International, Inc. Intracoastal Pointe Drive, Suite 404 Wayne Moor, Chief Executive Officer under Revolving Note ($3,000,000.00) advised that we are counsel to the Mark
Read more →-DYAI
Oct 1, 2007Dyadic Announces Senior Management Changes and Other Events
Announces Senior Management Changes and Other Events Fla - October 1, 2007 - Dyadic International, Inc. (AMEX: DIL) announced today that on September 27, 2007, Dr. Glenn E. Nedwin resigned from all positions Dyadic International, Inc. (the "Company"), including his positions a
Read more →-DYAI
Sep 24, 2007Dyadic Announces Termination of Employment of its President and CEO, Mark A. Emalfarb
Announces Termination of Employment of its President and CEO, Mark A. Fla - September 24, 2007 - Dyadic International, Inc. (AMEX: DIL) announced today that on September 20, 2007, a special committee (the "Special Committee") of the board of directors (the "Board") of Dyadic I
Read more →-DYAI
Aug 28, 2007Dyadic's Receives Notice of Continuing Failure to Satisfy Certain Amex Continued Listing Standards
Receives Notice of Continuing Failure to Satisfy Certain Amex Continued Listing Fla - August 28, 2007 - Dyadic International, Inc. (AMEX: DIL) announced today that it has received a second notice from The American Stock Exchange (the "Amex") indicating that the Company continu
Read more →-DYAI
Jul 9, 2007Dyadic's Amex Listing Will Be Continued Pursuant To An Extension
Amex Listing Will Be Continued Pursuant To An Extension Fla - July 9, 2007 - Dyadic International, Inc. (AMEX: DIL) announced today it has received notice from The American Stock Exchange (the "Amex") that Amex listing is being continued pursuant to an extension. 21, 2007, th
Read more →-DYAI
May 21, 2007Dyadic Updates Progress of Its Investigation Company announces its intent to abandon its Hong Kong and Mainland China operations Company reports receipt of delinquency notice from the American Stock Exchange
Updates Progress of Its Investigation announces its intent to abandon its Hong Kong and Mainland China reports receipt of delinquency notice from the American Stock Fla - May 21, 2007 - Dyadic International, Inc. (AMEX: DIL) today provided update on the progress of its invest
Read more →-DYAI
Apr 24, 2007Dyadic Announces Discovery of Potentially Material Operational and Financial Improprieties at its Hong Kong and Mainland China Operations
Announces Discovery of Potentially Operational and Financial Improprieties at its Hong Kong and Mainland China Fla. - April 24, 2007 - Dyadic International, Inc. (AMEX: DIL) today announced that it has discovered potentially material operational and financial improprieties at
Read more →-DYAI
Nov 20, 2006DYADIC ANNOUNCES $13 MILLION PRIVATE PLACEMENT Jupiter, Florida
ANNOUNCES $13 MILLION PRIVATE PLACEMENT Florida, November 20, 2006 - Dyadic International, Inc. (AMEX: biotechnology company, announced today that on November 17, 2006, it entered into a definitive agreement with institutional investors to purchase in a private placement 2,78
Read more →-DYAI
Oct 27, 2006Abengoa Press Release DYADIC ENTERS INTO RESEARCH AND DEVELOPMENT AGREEMENT WITH ABENGOA BIOENERGY IN THE AREA OF CELLULOSIC ETHANOL PRODUCTION ABENGOA BIOENERGY TO PURCHASE $10 MILLION OF DYADIC COMMON STOCK Jupiter, Fl
ENTERS INTO RESEARCH AND DEVELOPMENT AGREEMENT WITH ABENGOA BIOENERGY IN THE AREA OF CELLULOSIC ETHANOL PRODUCTION BIOENERGY TO PURCHASE $10 MILLION OF DYADIC COMMON STOCK Florida, October 27, 2006. Dyadic International, Inc. (AMEX: biotechnology company, today announced that
Read more →-DYAI
May 4, 2006Dyadic Press Release Dated 5/04/06 Dyadic Increases Ownership in its Asian Subsidiary to 100%
Increases Ownership in its Asian Subsidiary to 100% Fla. - May 4, 2006 - Dyadic International, Inc. (AMEX: DIL), a global biotechnology company (the "Company"), with subsidiaries in Hong Kong and mainland China, Poland, and The Netherlands, announced today that on April 2006,
Read more →-DYAI
May 2, 2006Press Release dated
Receives $2.1 Million in Cash from Exercise of Warrants and Stock Options and Announces $1.6 Million Debt-for-Equity Conversion by its Two Largest Stockholders, including the Company's Fla. - May 3, 2006 - Dyadic International, Inc. (AMEX: DIL), a biotechnology company, annou
Read more →-DYAI
Mar 21, 2006Glenn Nedwin, Ph.D., MBA, Co-Founder and President of Novozymes, Inc., to Join Dyadic International as Chief Scientific Officer and President of its Biosciences Business
Nedwin, Ph.D., MBA, Co-Founder and President of Novozymes, Inc., to Join Dyadic International as Chief Scientific Officer and President of its Biosciences Fla. - March 21, 2006 - (via Business Wire) - Dyadic International, Inc. (AMEX: DIL), biotechnology company, announced to
Read more →-DYAI
Dec 21, 2005TERMINATION AND LICENSE AGREEMENT THIS TERMINATION AND LICENSE AGREEMENT (this " Agreement ") is made as of the 19th day of December and effective as of
AND LICENSE AGREEMENT TERMINATION AND LICENSE AGREEMENT (this "Agreement") is December and effective as of November 23, 2005 (the "Effective corporation ("Dyadic International (USA), Inc., Florida, USA corporation ("Dyadic International, Inc., Delaware, USA corporation ("D
Read more →-DYAI
Apr 28, 2005v017127_ex99-1.txt DYADIC INTERNATIONAL, INC. INDEMNIFICATION AGREEMENT This Indemnification Agreement ("Agreement") is made as of the 26th day of April, 2005, by and between DYADIC INTERNATIONAL, INC., a Delaware corpor
DYADIC INTERNATIONAL, INC. INDEMNIFICATION AGREEMENT This Indemnification Agreement ("Agreement") is made as of the 26th day of April, 2005, by and between DYADIC INTERNATIONAL, INC., a Delaware corporation (the "Company"), and Harry Rosengart ("Indemnitee"). A. The Company
Read more →-DYAI
Apr 15, 2005v016572_ex99-1.txt [logo] Dyadic International, Inc. Dyadic International, Inc. 140 Intracoastal Pointe Drive, Suite 404 Jupiter, FL 33477 (561) 743-8333 http://www.dyadic-group.com --------------------------------------
[logo] Dyadic International, Inc. Dyadic International, Inc. 140 Intracoastal Pointe Drive, Suite 404 http://www.dyadic-group.com -------------------------------------------------------------------------------- DYADIC REPORTS YEAR-END 2004 FINANCIAL RESULTS Jupiter, Florida
Read more →-DYAI
Apr 1, 20051.txt DYADIC INTERNATIONAL, INC. INDEMNIFICATION AGREEMENT This Indemnification Agreement ("Agreement") is made as of the 29th day of March, 2005, by and between DYADIC INTERNATIONAL, INC., a Delaware corporation (the "C
DYADIC INTERNATIONAL, INC. INDEMNIFICATION AGREEMENT This Indemnification Agreement ("Agreement") is made as of the 29th day of March, 2005, by and between DYADIC INTERNATIONAL, INC., a Delaware corporation (the "Company"), and Robert Shapiro ("Indemnitee"). A. The Company a
Read more →-DYAI
Feb 1, 20051.txt EXECUTIVE EMPLOYMENT AGREEMENT THIS EXECUTIVE EMPLOYMENT AGREEMENT ("Agreement") is made and entered into as of the 31st day of January, 2005, by and between DYADIC INTERNATIONAL, INC., a Delaware corporation (the
EXECUTIVE EMPLOYMENT AGREEMENT THIS EXECUTIVE EMPLOYMENT AGREEMENT ("Agreement") is made and entered into as of the 31st day of January, 2005, by and between DYADIC INTERNATIONAL, INC., a Delaware corporation (the "Company"), and WAYNE MOOR (the "Executive"). The Company and
Read more →-DYAI
Jan 10, 2005v011187_ex99-1.txt DYADIC INTERNATIONAL, INC. STATEMENT OF DIRECTOR COMPENSATION POLICY THIS STATEMENT OF DIRECTOR COMPENSATION POLICY (the "Director Compensation Policy") sets forth the policies of Dyadic International,
DYADIC INTERNATIONAL, INC. DIRECTOR COMPENSATION POLICY THIS STATEMENT OF DIRECTOR COMPENSATION POLICY (the "Director Compensation Policy") sets forth the policies of Dyadic International, Inc, a Delaware corporation (the "Company") pertaining to the remuneration which the C
Read more →Competitive Position
How DYAI ranks across every disease it competes inCompetitive Position is a premium feature
See how DYAI ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial